학술논문

TATTON Phase Ib expansion cohort: Osimertinib plus savolitinib for patients (pts) with EGFR-mutant, MET-amplified NSCLC after progression on prior third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI)
Document Type
Journal
Source
CANCER RESEARCH; JUL 2019, 79 13, 2p. Supplement: S
Subject
Language
English
ISSN
15387445